To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
SB649868 is an orexin receptor antagonist in development by GlaxoSmithKline. Currently in Phase 2 development, this drug for sleep disorders is one of two such compounds currently in development, the other being Actelion's ACT-078573.
Additional recommended knowledge
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "SB649868". A list of authors is available in Wikipedia.|